Other News To Note
Wednesday, March 21, 2012
Halo Therapeutics LLC, of Newton, Mass., said the independent TREAT-NMD Advisory Committee on Therapeutics offered a favorable review of HT-100, Halo's drug candidate for Duchenne's muscular dystrophy, endorsing the company's plan to move the drug candidate to a clinical trial. HT-100, a formulation of halofuginone, is an orally available small-molecule drug candidate designed to reduce fibrosis and promote healthy muscle fiber regeneration.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.